Skip to content

Barebacking: not a simple phenemenon, US research shows

Tipranavir enters phase III trials

Think HIV: Routine HIV screening programme captures undiagnosed infections

HIV transmission rate ten times higher during primary infection

Atazanavir and amprenavir both pitching for first line therapy with new resistance data

New antiretrovirals: `pipeline at its fullest for years`

New protease inhibitor TMC 114 effective for PI-exhausted patients in early study

T-1249 could salvage T-20 failure

HIV antibodies revived as microbicide